An experimental drug from GlaxoSmithKline to relieve symptoms of chronic obstructive pulmonary disease, or COPD, was recommended for marketing approval in Europe, the drug maker said Friday.
via WSJ.com: US Business http://ift.tt/MH7sO4
via WSJ.com: US Business http://ift.tt/MH7sO4
Nessun commento:
Posta un commento